Doral (Quazepam Tablets)
برای این دارو، اطلاعات عمومی (فارسی) یافت نشد . برای افزودن اطلاعات فارسی به این دارو کلیک نمایید.
Doral (Quazepam Tablets)

DORAL®
(quazepam) Tablets

DRUG DESCRIPTION

DORAL® (brand of quazepam) Tablets contain quazepam, a trifluoroethyl benzodiazepine hypnotic agent, having the chemical name 7-chloro-5- (o-fluoro-phenyl)-1,3-dihydro-1-(2,2,2-trifluoroethyl)-2H­1,4-benzodiazepine-2-thione and the following structural formula:

DORAL  ( quazepam) Structural Formula Illustration

Quazepam has the empirical formula C17H11CIF4N2S, and a molecular weight of 386.8. It is a white crystalline compound, soluble in ethanol and insoluble in water. Each DORAL® Tablet contains either 7.5 or 15 mg of quazepam. The inactive ingredients for DORAL® (quazepam tablets) Tablets 7.5 or 15 mg include cellulose, corn starch, FD&C Yellow No. 6 Al Lake, lactose, magnesium stearate, silicon dioxide, and sodium lauryl sulfate.

What are the possible side effects of quazepam (Doral)?

Stop using quazepam and call your doctor at once if you have a serious side effect such as:

  • worsening insomnia;
  • confusion, anxiety, slurred speech, unusual thoughts or behavior;
  • hallucinations, agitation, aggression;
  • weak or shallow breathing;
  • fast or pounding heartbeats;
  • muscle stiffness in your tongue, jaw, or neck;
  • problems with urination; or
  • jaundice (yellowing of the skin or eyes).

Less serious side effects may include:

  • daytime drowsiness (or during hours when you are not normally...

Read All Potential Side Effects and See Pictures of Doral »

What are the precautions when taking quazepam tablets (Doral)?

Before taking quazepam, tell your doctor or pharmacist if you are allergic to it; or to other benzodiazepines (e.g., lorazepam, diazepam); or if you have any other allergies. This product may contain inactive ingredients, which can cause allergic reactions or other problems. Talk to your pharmacist for more details.

Before using this medication, tell your doctor or pharmacist your medical history, especially of: liver disease, kidney disease, mental/mood problems (e.g., depression, panic disorder), lung problems (e.g., pulmonary insufficiency, sleep apnea), seizures, personal or family history of regular use/abuse of drugs/alcohol/other substances.

This drug may make you dizzy or drowsy or cause temporary blurred vision. Do not drive, use machinery, or do any activity that...

Read All Potential Precautions of Doral »

Last reviewed on RxList: 4/30/2010
This monograph has been modified to include the generic and brand name in many instances.

INDICATIONS

DORAL® (quazepam tablets) Tablets are indicated for the treatment of insomnia characterized by difficulty in falling asleep, frequent nocturnal awakenings, and/or early morning awakenings. The effectiveness of DORAL® (quazepam tablets) has been established in placebo-controlled clinical studies of 5 nights duration in acute and chronic insomnia. The sustained effectiveness of DORAL® (quazepam tablets) has been established in chronic insomnia in a sleep lab (polysomnographic) study of 28 nights duration.

Because insomnia is often transient and intermittent, the prolonged administration of DORAL® (quazepam tablets) Tablets is generally not necessary or recommended. Since insomnia may be a symptom of several other disorders, the possibility that the complaint may be related to a condition for which there is a more specific treatment should be considered.

DOSAGE AND ADMINISTRATION

Adults: Initiate therapy at 15 mg until individual responses are determined. In some patients, the dose may then be reduced to 7.5 mg.

Elderly and Debilitated Patients: Because the elderly and debilitated may be more sensitive to benzodiazepines, attempts to reduce the nightly dosage after the first 1-2 nights of therapy are suggested.

Geriatric Patients: A double-blind controlled sleep laboratory study (N=30) compared the effects of quazepam 7.5 mg and 15 mg to that of placebo over a period of 7 days. Both the 7.5 mg and 15 mg doses appeared to be well tolerated. Caution must be used in interpreting this data due to the small size of the study; therefore, initiate therapy in geriatric patients at 7.5 mg. If not effective after 1-2 nights, the dosage may be increased to 15 mg.

HOW SUPPLIED

DORAL® (quazepam tablets) Tablets, 7.5 mg, unscored, capsule-shaped, light orange, slightly white speckled tablets, impressed with the product identification number 7.5 on one side of the tablet, and the product name (DORAL (quazepam tablets) ) on the other.

7.5 mg Bottles of 100 NDC 63004-7735-1

DORAL® (quazepam tablets) Tablets, 15 mg, unscored, capsule-shaped, light orange, slightly white speckled tablets, impressed with the product identification number 15 on one side of the tablet, and the product name (DORAL (quazepam tablets) ) on the other.

15 mg Bottles of 100 NDC 63004-7734-1

Store DORAL® (quazepam tablets) Tablets at controlled room temperature 20°-25°C (68°-77°F).

Manufactured for: Questcor Pharmaceuticals, Inc. Union City, CA 94587 USA. Manufactured by: MedPointe Pharmaceuticals, MedPointe Healthcare Inc. Somerset, NJ 08873. Under license from Baker Norton Pharmaceuticals Inc.

Last reviewed on RxList: 4/30/2010
This monograph has been modified to include the generic and brand name in many instances.

SIDE EFFECTS

Adverse events most frequently encountered in patients treated with quazepam are drowsiness and headache.

Accurate estimates of the incidence of adverse events associated with the use of any drug are difficult to obtain. Estimates are influenced by drug dose, detection technique, setting, physician judgments, etc. Consequently, the table below is presented solely to indicate the relative frequency of adverse events reported in representative controlled clinical studies conducted to evaluate the safety and efficacy of quazepam. The figures cited cannot be used to predict precisely the incidence of such events in the course of usual medical practice. These figures, also, cannot be compared with those obtained from other clinical studies involving related drug products and placebo.

The figures cited below are estimates of untoward clinical event incidences of 1% or greater among subjects who participated in the relatively short-duration, placebo-controlled clinical trials of quazepam.

NUMBER OF PATIENTS DORAL®*
267
PLACEBO
268
% OF PATIENTS REPORTING
Central Nervous System
  Daytime Drowsiness 12.0 3.3
  Headache 4.5 2.2
  Fatigue 1.9 0
  Dizziness 1.5 < 1
Autonomic Nervous System
  Dry Mouth 1.5 < 1
Gastrointestinal System
  Dyspepsia 1.1 < 1
* DORAL® 15 mg

The following incidences of laboratory abnormalities occurred at a rate of 1% or greater in patients receiving quazepam and the corresponding placebo group. None of these changes were considered to be of physiological significance.

NUMBER OF PATIENTS DORAL®
234
PLACEBO
244
% OF PATIENTS REPORTING Low High Low High
Hematology
  Hemoglobin 1.4 0 1.2 0
  Hematocrit 1.5 0 1.7 0
  Lymphocyte 1.3 1.6 1.2 1.9
  Eosinophil * 1.5 * 1.3
  SEG 1.1 * 1.6 *
  Monocyte * 1.1 * *
Blood Chemistry
  Glucose * * * 1.2
  SGOT * 1.3 * 1.1
Urinalysis
  Specific Gravity * * * 1.1
  WBC 0 2.6 0 3.0
  RBC 0 * 0 1.1
  Epithelial Cells 0 2.5 0 3.2
  Crystals 0 * 0 1.0
*These laboratory abnormalities occurred in less than 1% of patients. In addition, abnormalities in the following laboratory tests were observed in less than 1% of the patients evaluated: WBC count, platelet count, total protein, albumin, BUN, creatinine, total bilirubin, alkaline phosphatase, and SGPT.

The following additional events occurred among individuals receiving quazepam at doses equivalent to or greater than those recommended during its clinical testing and development. There is no way to establish whether or not the administration of DORAL® (quazepam tablets) caused these events.

Hypokinesia, ataxia, confusion, incoordination, hyperkinesia, speech disorder, and tremor were reported.

Also, depression, nervousness, agitation, amnesia, anorexia, anxiety, apathy, euphoria, impotence, decreased libido, paranoid reaction, nightmares, abnormal thinking, abnormal taste perception, abnormal vision, and cataract were reported.

Also reported were urinary incontinence, palpitations, nausea, constipation, diarrhea, abdominal pain, pruritus, rash, asthenia, and malaise.

The following list provides an overview of adverse experiences that have been reported and are considered to be reasonably related to the administration of benzodiazepines: incontinence, slurred speech, urinary retention, jaundice, dysarthria, dystonia, changes in libido, irritability, and menstrual irregularities.

As with all benzodiazepines, paradoxical reactions such as stimulation, agitation, increased muscle spasticity, sleep disturbances, hallucinations, and other adverse behavioral effects may occur in rare instances and in a random fashion. Should these occur, use of the drug should be discontinued.

There have been reports of withdrawal signs and symptoms of the type associated with withdrawal from CNS depressant drugs following the rapid decrease or the abrupt discontinuation of benzodiazepines (see Drug Abuse And Dependence).

Drug Abuse And Dependence

Controlled Substance

DORAL® (quazepam tablets) is a controlled substance under the Controlled Substances Act and has been assigned by the Drug Enforcement Administration to Schedule IV.

Abuse and Dependence

Abuse and addiction are separate and distinct from physical dependence and tolerance. Abuse is characterized by misuse of the drug for non-medical purposes, often in combination with other psychoactive substances. Physical dependence is a state of adaptation that is manifested by a specific withdrawal syndrome that can be produced by abrupt cessation, rapid dose reduction, decreasing blood level of the drug and/or administration of an antagonist. Tolerance is a state of adaptation in which exposure to a drug induces changes that result in a diminution of one or more of the drug's effects over time. Tolerance may occur to both the desired and undesired effects of drugs and may develop at different rates for different effects.

Addiction is a primary, chronic, neurobiological disease with genetic, psychosocial, and environmental factors influencing its development and manifestations. It is characterized by behaviors that include one or more of the following: impaired control over drug use, compulsive use, continued use despite harm, and craving. Drug addiction is a treatable disease, utilizing a multidisciplinary approach, but relapse is common.

Withdrawal symptoms, similar in character to those noted with barbiturates and alcohol (e.g., convulsions, tremor, abdominal and muscle cramps, vomiting, and sweating), have occurred following abrupt discontinuance of benzodiazepines. The more severe withdrawal symptoms have usually been limited to those patients who received excessive doses over an extended period of time. Generally milder withdrawal symptoms (e.g., dysphoria and insomnia) have been reported following abrupt discontinuance of benzodiazepines taken continuously at therapeutic levels for several months. Consequently, after extended therapy, abrupt discontinuation should generally be avoided and a gradual dosage tapering schedule followed. Addiction-prone individuals (such as drug addicts or alcoholics) should be under careful surveillance when receiving quazepam or other psychotropic agents because of the predisposition of such patients to habituation and dependence.

Read the Doral (quazepam tablets) Side Effects Center for a complete guide to possible side effects »

DRUG INTERACTIONS

The benzodiazepines, including DORAL® (quazepam tablets) Tablets, produce additive CNS depressant effects when co-administered with psychotropic medications, anticonvulsants, antihistaminics, ethanol, and other drugs which produce CNS depression.

Quazepam is a mechanism based inhibitor of CYP2B6 based on an in vitro study. However, the in vivo extrapolation of this is unknown. It may be possible that co-administration of DORAL® (quazepam tablets) and drugs primarily metabolized by CYP2B6 (e.g., efavirenz and bupropion) may result in increased plasma concentrations of these drugs resulting in an increase in adverse events (e.g., CNS toxicities associated with efavirenz and precipitation of seizures with bupropion). Patients taking medications that are CYP2B6 substrates with DORAL® (quazepam tablets) should be monitored closely for adverse reactions associated with these medications. If adverse events are observed, clinicians may consider the discontinuation of DORAL® (quazepam tablets) and the selection of an alternative anxiolytic agent.

Last reviewed on RxList: 4/30/2010
This monograph has been modified to include the generic and brand name in many instances.

WARNINGS

Because sleep disturbances may be the presenting manifestation of a physical and/or psychiatric disorder, symptomatic treatment of insomnia should be initiated only after a careful evaluation of the patient. The failure of insomnia to remit after 7 to 10 days of treatment may indicate the presence of a primary psychiatric and/or medical illness that should be evaluated. Worsening of insomnia or the emergence of new thinking or behavior abnormalities may be the consequence of an unrecognized psychiatric or physical disorder. Such findings have emerged during the course of treatment with sedative-hypnotic drugs. Because some of the important adverse effects of sedative-hypnotics appear to be dose related (see PRECAUTIONS and DOSAGE AND ADMINISTRATION), it is important to use the smallest possible effective dose, especially in the elderly.

Complex behaviors such as “sleep-driving” (i.e., driving while not fully awake after ingestion of a sedative-hypnotic, with amnesia for the event) have been reported. These events can occur in sedativehypnotic-naive as well as in sedative-hypnotic-experienced persons. Although behaviors such as sleep driving may occur with sedative-hypnotics alone at therapeutic doses, the use of alcohol and other CNS depressants with sedative-hypnotics appears to increase the risk of such behaviors, as does the use of sedative-hypnotics at doses exceeding the maximum recommended dose. Due to the risk to the patient and the community, discontinuation of sedative-hypnotics should be strongly considered for patients who report a “sleep-driving” episode.

Other complex behaviors (e.g., preparing and eating food, making phone calls, or having sex) have been reported in patients who are not fully awake after taking a sedative-hypnotic. As with sleep-driving, patients usually do not remember these events.

Severe anaphylactic and anaphylactoid reactions

Rare cases of angioedema involving the tongue, glottis or larynx have been reported in patients after taking the first or subsequent doses of sedative-hypnotics, including Doral (quazepam tablets) . Some patients have had additional symptoms such as dyspnea, throat closing, or nausea and vomiting that suggest anaphylaxis.

Some patients have required medical therapy in the emergency department. If angioedema involves the tongue, glottis or larynx, airway obstruction may occur and be fatal. Patients who develop angioedema after treatment with Doral (quazepam tablets) should not be rechallenged with the drug.

Patients receiving benzodiazepines should be cautioned about possible combined effects with alcohol and other CNS depressants. Also, caution patients that an additive effect may occur if alcoholic beverages are consumed during the day following the use of benzodiazepines for nighttime sedation. The potential for this interaction continues for several days following their discontinuance until serum levels of psychoactive metabolites have declined.

Patients should also be cautioned about engaging in hazardous occupations requiring complete mental alertness, such as operating machinery or driving a motor vehicle, after ingesting benzodiazepines, including potential impairment of the performance of such activities which may occur the day following ingestion.

Withdrawal symptoms of the type associated with sedatives/hypnotics (e.g., barbiturates, bromides, etc.) and alcohol have been reported after the discontinuation of benzodiazepines. While these symptoms have been more frequently reported after the discontinuation of excessive benzodiazepine doses, there have also been controlled studies demonstrating the occurrence of such symptoms after discontinuation of therapeutic doses of benzodiazepines, generally following prolonged use (but in some instances after periods as brief as 6 weeks). It is generally believed that the gradual reduction of dosage will diminish the occurrence of such symptoms (see Drug Abuse And Dependence).

PRECAUTIONS

General

Impaired motor and/or cognitive performance attributable to the accumulation of benzodiazepines and their active metabolites following several days of repeated use at their recommended doses is a concern in certain vulnerable patients (e.g., those especially sensitive to the effects of benzodiazepines or those with a reduced capacity to metabolize and eliminate them). Consequently, elderly or debilitated patients and those with impaired renal or hepatic function should be cautioned about the risk and advised to monitor themselves for signs of excessive sedation or impaired coordination.

The possibility of respiratory depression in patients with chronic pulmonary insufficiency should be considered.

When benzodiazepines are administered to depressed patients, there is a risk that the signs and symptoms of depression may be intensified. Consequently, appropriate precautions (e.g., limiting the total prescription size and increased monitoring for suicidal ideation) should be considered.

Laboratory Tests

Laboratory tests are not ordinarily required in otherwise healthy patients when quazepam is used as recommended.

Carcinogenesis, Mutagenesis, Impairment of Fertility

Quazepam showed no evidence of carcinogenicity or other significant pathology in oral oncogenicity studies in mice and hamsters.

Quazepam was tested for mutagenicity using the L5178Y TK +/-Mouse Lymphoma Mutagenesis Assay and the Ames Test. The L5178Y TK +/-Assay was equivocal and the Ames Test did not show mutagenic activity.

Reproduction studies in mice conducted with quazepam at doses equal to 60 and 180 times the human dose of 15 mg, and with diazepam at 67 times the human dose, produced slight reductions in the pregnancy rate. Similar reduction in pregnancy rates have been reported in mice dosed with other benzodiazepines, and is believed to be related to the sedative effects of these drugs at high doses.

Pregnancy

Teratogenic Effects

Pregnancy Category X (See CONTRAINDICATIONS, Usage in Pregnancy) Reproduction studies of quazepam in mice at doses up to 400 times the human dose revealed no major drug-related malformations. Minor developmental variations that occurred were delayed ossification of the sternum, vertebrae, distal phalanges and supraoccipital bones, at doses of 66 and 400 times the human dose. Studies with diazepam at 200 times the human dose showed a similar or greater incidence than quazepam. A reproduction study of quazepam in New Zealand rabbits at doses up to 134 times the human dose demonstrated no effect on fetal morphology or development of offspring.

Nonteratogenic Effects

The child born of a mother who is taking benzodiazepines may be at some risk of withdrawal symptoms from the drug during the postnatal period. Neonatal flaccidity has been reported in children born of mothers who had been receiving benzodiazepines.

Labor and Delivery

DORAL® (quazepam tablets) Tablets have no established use in labor or delivery.

Nursing Mothers

Quazepam and its metabolites are excreted in the milk of lactating women. Therefore, administration of DORAL® (quazepam tablets) Tablets to nursing women is not recommended.

Pediatric Use

Safety and effectiveness in children below the age of 18 years have not been established.

Geriatric Use

In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.

Last reviewed on RxList: 4/30/2010
This monograph has been modified to include the generic and brand name in many instances.

OVERDOSE

Manifestations of overdosage seen with other benzodiazepines include somnolence, confusion, and coma. In the event that an overdose occurs, the following is the recommended treatment. Respiration, pulse, and blood pressure should be monitored, as in all cases of drug overdosage. General supportive measures should be employed, along with immediate gastric lavage. Intravenous fluids should be administered and an adequate airway maintained. Hypotension may be treated with the use of norepinephrine bitartrate or metaraminol bitartrate. Dialysis is of limited value. Animal experiments suggest that forced diuresis or hemodialysis are probably of little value in treating overdosage. As with the management of intentional overdosing with any drug, it should be borne in mind that multiple agents may have been ingested.

The oral LD50 in mice was greater than 5000 mg/kg.

CONTRAINDICATIONS

DORAL® (quazepam tablets) Tablets are contraindicated in patients with known hypersensitivity to this drug or other benzodiazepines, and in patients with established or suspected sleep apnea.

Usage in Pregnancy

Benzodiazepines may cause fetal damage when administered during pregnancy. An increased risk of congenital malformations associated with the use of diazepam and chlordiazepoxide during the first trimester of pregnancy has been suggested in several studies. Transplacental distribution has resulted in neonatal CNS depression following the ingestion of therapeutic doses of a benzodiazepine hypnotic during the last weeks of pregnancy.

DORAL® (quazepam tablets) Tablets are contraindicated in pregnancy because the potential risks outweigh the possible advantages of their use during this period. If there is a likelihood of the patient becoming pregnant while receiving DORAL® (quazepam tablets) , she should be warned of the potential risk to the fetus. Patients should be instructed to discontinue the drug prior to becoming pregnant. The possibility that a woman of child-bearing potential may be pregnant at the time of institution of therapy should be considered. (see Pregnancy, Teratogenic Effects: Pregnancy Category X).

Last reviewed on RxList: 4/30/2010
This monograph has been modified to include the generic and brand name in many instances.

CLINICAL PHARMACOLOGY

Central nervous system agents of the 1,4-benzodiazepine class presumably exert their effects by binding to stereo-specific receptors at several sites within the central nervous system (CNS). Their exact mechanism of action is unknown.

In a sleep laboratory study, DORAL® (quazepam tablets) Tablets significantly decreased sleep latency and total wake time, and significantly increased total sleep time and percent sleep time, for one or more nights. Quazepam 15 mg was effective on the first night of administration. Sleep latency, total wake time and wake time after sleep onset were still decreased and percent sleep time was still increased for several nights after the drug was discontinued. Percent slow wave sleep was decreased, and REM sleep was essentially unchanged. No transient sleep disturbance, such as “rebound insomnia,” was observed after withdrawal of the drug in sleep laboratory studies in 12 patients using 15 mg doses.

In outpatient studies, DORAL® (quazepam tablets) Tablets improved all subjective measures of sleep including sleep induction time, duration of sleep, number of nocturnal awakenings, occurrence of early morning awakening, and sleep quality. Some effects were evident on the first night of administration of DORAL® (quazepam tablets) Tablets (sleep induction time, number of nocturnal awakenings, and duration of sleep). Residual medication effects (“hangover”) were minimal.

Quazepam is rapidly (absorption half-life of about 30 minutes) and well absorbed from the gastrointestinal tract. The peak plasma concentration of quazepam is approximately 20 ng/mL after a 15 mg dose and is obtained at about 2 hours. Quazepam, the active parent compound, is extensively metabolized in the liver; two of the plasma metabolites are 2-oxoquazepam and N-desalkyl-2-oxoquazepam. All three compounds show pharmacological central nervous system activity in animals.

Following administration of 14C-quazepam, approximately 31% of the dose appears in the urine and 23% in the feces over a five-day period; only trace amounts of unchanged drug are present in the urine.

The mean elimination half-life of quazepam and 2-oxoquazepam is 39 hours and that of N-desalkyl-2oxoquazepam is 73 hours. Steady-state levels of quazepam and 2-oxoquazepam are attained by the seventh daily dose and that of N-desalkyl-2-oxoquazepam by the thirteenth daily dose.

The pharmacokinetics of quazepam and 2-oxoquazepam in geriatric subjects are comparable to those seen in young adults; as with desalkyl metabolites of other benzodiazepines, the elimination half-life of N-desalkyl-2oxoquazepam in geriatric patients is about twice that of young adults.

The degree of plasma protein binding for quazepam and its two major metabolites is greater than 95%. The absorption, distribution, metabolism, and excretion of benzodiazepines may be altered in various disease states including alcoholism, impaired hepatic function, and impaired renal function.

The type and duration of hypnotic effects and the profile of unwanted effects during administration of benzodiazepine drugs may be influenced by the biologic half-life of administered drug and any active metabolites formed. When half-lives are long, drug or metabolites may accumulate during periods of nightly administration and be associated with impairments of cognitive and/or motor performance during waking hours; the possibility of interaction with other psychoactive drugs or alcohol will be enhanced. In contrast, if half-lives are short, drug and metabolites will be cleared before the next dose is ingested, and carry-over effects related to excessive sedation or CNS depression should be minimal or absent. However, during nightly use for an extended period, pharmacodynamic tolerance or adaptation to some effects of benzodiazepine hypnotics may develop. If the drug has a short half-life of elimination, it is possible that a relative deficiency of the drug or its active metabolites (i.e., in relationship to the receptor site) may occur at some point in the interval between each night's use. This sequence of events may account for two clinical findings reported to occur after several weeks of nightly use of rapidly eliminated benzodiazepine hypnotics, namely, increased wakefulness during the last third of the night, and the appearance of increased signs of daytime anxiety in selected patients.

Quazepam crosses the placental barrier of mice. Quazepam, 2-oxoquazepam and N-desalkyl-2oxoquazepam are present in breast milk of lactating women, but the total amount found in the milk represents only about 0.1% of the administered dose.

Drug-Drug Interactions

(see also PRECAUTIONS: DRUG INTERACTIONS)

In vitro inhibition studies conducted to assess the potential of quazepam to inhibit CYP2B6, CYP2C8 and CYP2E1 at relevant clinical Cmax concentrations (0.15 μM = 58 ng/mL) demonstrate quazepam is a CYP2B6 mechanism based inhibitor. Increased plasma concentrations of drugs that are substrates of CYP2B6 may result if coadministered with DORAL®. Quazepam does not inhibit CYP2C8 and CYP2E1.

Last reviewed on RxList: 4/30/2010
This monograph has been modified to include the generic and brand name in many instances.

PATIENT INFORMATION

Prescribers or other health professionals should inform patients, their families, and their caregivers about the benefits and risks associated with treatment with Doral (quazepam tablets) and should counsel them in its appropriate use. A patient Medication Guide is available for Doral (quazepam tablets) . The prescriber or health professional should instruct patients, their families, and their caregivers to read the Medication Guide and should assist them in understanding its contents. Patients should be given the opportunity to discuss the contents of the Medication Guide and to obtain answers to any questions they may have.

Patients should be advised of the following issues and asked to alert their prescriber if these occur while taking Doral (quazepam tablets) .

“Sleep-Driving“ and other complex behaviors

There have been reports of people getting out of bed after taking a sedative-hypnotic and driving their cars while not fully awake, often with no memory of the event. If a patient experiences such an episode, it should be reported to his or her doctor immediately, since “sleep-driving” can be dangerous. This behavior is more likely to occur when sedative-hypnotics are taken with alcohol or other central nervous system depressants (see WARNINGS). Other complex behaviors (e.g., preparing and eating food, making phone calls, or having sex) have been reported in patients who are not fully awake after taking a sedative-hypnotic. As with sleep-driving, patients usually do not remember these events.

It is also suggested that physicians discuss the following information with patients. This information is intended to aid in the safe and effective use of this medication. It is not a disclosure of all possible adverse or intended effects.

  1. Inform your physician about any alcohol consumption and medicine you are taking now, including drugs you may buy without a prescription. Alcohol should generally not be used during treatment with hypnotics.
  2. Inform your physician if you are planning to become pregnant, if you are pregnant, or if you become pregnant while you are taking this medicine.
  3. Inform your physician if you are nursing.
  4. Until you experience how this medicine affects you, do not drive a car or operate potentially dangerous machinery, etc.
  5. Benzodiazepines may cause daytime sedation, which may persist for several days following drug discontinuation.
  6. Patients should be told not to increase the dose on their own and should inform their physician if they believe the drug “does not work anymore”.
  7. If benzodiazepines are taken on a prolonged and regular basis (even for periods as brief as 6 weeks), patients should be advised not to stop taking them abruptly or to decrease the dose without consulting their physician, because withdrawal symptoms may occur.

Last reviewed on RxList: 4/30/2010
This monograph has been modified to include the generic and brand name in many instances.

>

PATIENT INFORMATION

Prescribers or other health professionals should inform patients, their families, and their caregivers about the benefits and risks associated with treatment with Doral (quazepam tablets) and should counsel them in its appropriate use. A patient Medication Guide is available for Doral (quazepam tablets) . The prescriber or health professional should instruct patients, their families, and their caregivers to read the Medication Guide and should assist them in understanding its contents. Patients should be given the opportunity to discuss the contents of the Medication Guide and to obtain answers to any questions they may have.

Patients should be advised of the following issues and asked to alert their prescriber if these occur while taking Doral (quazepam tablets) .

“Sleep-Driving“ and other complex behaviors

There have been reports of people getting out of bed after taking a sedative-hypnotic and driving their cars while not fully awake, often with no memory of the event. If a patient experiences such an episode, it should be reported to his or her doctor immediately, since “sleep-driving” can be dangerous. This behavior is more likely to occur when sedative-hypnotics are taken with alcohol or other central nervous system depressants (see WARNINGS). Other complex behaviors (e.g., preparing and eating food, making phone calls, or having sex) have been reported in patients who are not fully awake after taking a sedative-hypnotic. As with sleep-driving, patients usually do not remember these events.

It is also suggested that physicians discuss the following information with patients. This information is intended to aid in the safe and effective use of this medication. It is not a disclosure of all possible adverse or intended effects.

  1. Inform your physician about any alcohol consumption and medicine you are taking now, including drugs you may buy without a prescription. Alcohol should generally not be used during treatment with hypnotics.
  2. Inform your physician if you are planning to become pregnant, if you are pregnant, or if you become pregnant while you are taking this medicine.
  3. Inform your physician if you are nursing.
  4. Until you experience how this medicine affects you, do not drive a car or operate potentially dangerous machinery, etc.
  5. Benzodiazepines may cause daytime sedation, which may persist for several days following drug discontinuation.
  6. Patients should be told not to increase the dose on their own and should inform their physician if they believe the drug “does not work anymore”.
  7. If benzodiazepines are taken on a prolonged and regular basis (even for periods as brief as 6 weeks), patients should be advised not to stop taking them abruptly or to decrease the dose without consulting their physician, because withdrawal symptoms may occur.

Last reviewed on RxList: 4/30/2010
This monograph has been modified to include the generic and brand name in many instances.

Disclaimer

Doral Consumer

IMPORTANT: HOW TO USE THIS INFORMATION: This is a summary and does NOT have all possible information about this product. This information does not assure that this product is safe, effective, or appropriate for you. This information is not individual medical advice and does not substitute for the advice of your health care professional. Always ask your health care professional for complete information about this product and your specific health needs.

QUAZEPAM - ORAL

(KWAY-zeh-pam)

COMMON BRAND NAME(S): Doral

USES: This medication is used for the short-term treatment of patients with trouble sleeping (insomnia). It is generally used for 7-10 days. It may help you fall asleep faster and decrease the number of times you awaken during the night. It may also help you sleep for a longer period of time. Quazepam belongs to a class of medications called sedative/hypnotics. It acts on your brain to produce a calming effect.

HOW TO USE: Read the Medication Guide provided by your pharmacist before you start using quazepam and each time you get a refill. If you have any questions regarding the information, consult your doctor or pharmacist.

Take this medication by mouth, with or without food, usually once nightly, 30 minutes before bedtime; or take as directed by your doctor. The dosage is based on your medical condition and response to therapy.

Although unlikely, this drug can infrequently cause temporary memory loss. To avoid this effect, do not take a dose of this drug unless you have time for a full night's sleep that lasts at least 7-8 hours. For example, do not take this drug during an overnight plane flight of less than 8 hours.

This medication may cause withdrawal reactions, especially if it has been used regularly for a long time or in high doses. In such cases, withdrawal symptoms (such as unusual depressed/anxious mood, stomach/muscle cramps, vomiting, sweating, shakiness, seizures) may occur if you suddenly stop using this medication. To prevent withdrawal reactions, your doctor may reduce your dose gradually. Consult your doctor or pharmacist for more details, and report any withdrawal reactions immediately.

Although it is very unlikely to occur, this medication can also result in abnormal drug-seeking behavior (addiction/habit forming). Do not increase your dose, take it more frequently or use it for a longer period of time than prescribed. Properly stop the medication when so directed. This will lessen the chances of becoming addicted.

When used for an extended period, this medication may not work as well and may require different dosing. Talk with your doctor if this medication stops working well.

You may experience trouble sleeping the first few nights after you stop taking this medication. This is called rebound insomnia and it is normal. It will usually go away after 1-2 nights. If this effect continues, contact your doctor.

Inform your doctor if your condition persists or worsens after 7-10 days.

Disclaimer

Doral Consumer (continued)

SIDE EFFECTS: Dizziness, loss of coordination, or blurred vision may occur. To minimize falls, remember to get up slowly when rising from a seated or lying position. If any of these effects persist or worsen, notify your doctor or pharmacist promptly.

This medication may make you sleepy during the day. Tell your doctor if you have daytime drowsiness. Your dose may need to be adjusted.

Remember that your doctor has prescribed this medication because he or she has judged that the benefit to you is greater than the risk of side effects. Many people using this medication do not have serious side effects.

Tell your doctor immediately if any of these unlikely but serious side effects occur: confusion, unusual feelings of well-being (euphoria), uncontrolled movements (tremor), restlessness, memory loss, sweating, mental/mood changes (e.g., hallucinations, agitation, anxiety, unusual/disturbing thoughts, depression, rare thoughts of suicide), increased or vivid dreams, vision changes, fainting.

Tell your doctor immediately if any of these rare but very serious side effects occur: signs of infection (e.g., fever, persistent sore throat), unusual paleness, unusual tiredness, fast/pounding/irregular heartbeat, yellowing of the eyes/skin, dark urine.

Some people who take sleep medications have reported getting out of bed and sleepwalking, driving, eating, talking on the phone, or having sex while not fully awake. Often they do not remember these activities. This problem can be dangerous to you or to others. If you find out that you have done any of these activities after taking this medication, tell your doctor immediately. Your risk is increased if you use alcohol or other medications that can make you drowsy while taking quazepam.

A very serious allergic reaction to this drug is unlikely, but seek immediate medical attention if it occurs. Symptoms of a serious allergic reaction may include: rash, itching/swelling (especially of the face/tongue/throat), severe dizziness, trouble breathing.

This is not a complete list of possible side effects. If you notice other effects not listed above, contact your doctor or pharmacist.

In the US -

Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

In Canada - Call your doctor for medical advice about side effects. You may report side effects to Health Canada at 1-866-234-2345.

Read the Doral (quazepam tablets) Side Effects Center for a complete guide to possible side effects »

PRECAUTIONS: Before taking quazepam, tell your doctor or pharmacist if you are allergic to it; or to other benzodiazepines (e.g., lorazepam, diazepam); or if you have any other allergies. This product may contain inactive ingredients, which can cause allergic reactions or other problems. Talk to your pharmacist for more details.

Before using this medication, tell your doctor or pharmacist your medical history, especially of: liver disease, kidney disease, mental/mood problems (e.g., depression, panic disorder), lung problems (e.g., pulmonary insufficiency, sleep apnea), seizures, personal or family history of regular use/abuse of drugs/alcohol/other substances.

This drug may make you dizzy or drowsy or cause temporary blurred vision. Do not drive, use machinery, or do any activity that requires alertness or clear vision until you are sure you can perform such activities safely. Avoid alcoholic beverages.

Caution is advised when using this drug in the elderly because they may be more sensitive to the effects of the drug, especially drowsiness, dizziness, loss of coordination, and confusion.

Quazepam must not be used during pregnancy. Other medications in this class have caused birth defects when used in the first three months of pregnancy. Other medications in this class have also caused unusual drowsiness, feeding problems, and liver problems in newborns when used at or near the time of delivery, or withdrawal symptoms in newborns when used for a long time during pregnancy. If you are a woman of childbearing age, use an effective form of birth control while taking this drug. If you plan to become pregnant, stop taking this drug before doing so. If you become pregnant or think you may be pregnant, inform your doctor immediately.

This medication passes into breast milk and may have undesirable effects on a nursing infant. Breast-feeding while using this drug is not recommended. Consult your doctor before breast-feeding.

Disclaimer

Doral Consumer (continued)

DRUG INTERACTIONS: Your healthcare professionals (e.g., doctor or pharmacist) may already be aware of any possible drug interactions and may be monitoring you for it. Do not start, stop or change the dosage of any medicine before checking with them first.

This drug should not be used with the following medication because very serious interactions may occur: sodium oxybate.

If you are currently using the medication listed above, tell your doctor or pharmacist before starting quazepam.

Before using this medication, tell your doctor or pharmacist of all prescription and nonprescription/herbal products you may use, especially of: cimetidine, clozapine, disulfiram, kava, nefazodone, certain SSRI antidepressants (fluoxetine, fluvoxamine).

Tell your doctor or pharmacist if you also take drugs that cause drowsiness such as: antihistamines that cause drowsiness (e.g., diphenhydramine), anti-anxiety drugs (e.g., diazepam), anti-seizure drugs (e.g., carbamazepine), other medicines for sleep (e.g., zolpidem), muscle relaxants, narcotic pain relievers (e.g., codeine), psychiatric medicines (e.g., phenothiazines such as chlorpromazine, or tricyclics such as amitriptyline), tranquilizers.

Check the labels on all your medicines (e.g., cough-and-cold products) because they may contain drowsiness-causing ingredients including alcohol. Ask your pharmacist about the safe use of those products.

This document does not contain all possible interactions. Therefore, before using this product, tell your doctor or pharmacist of all the products you use. Keep a list of all your medications with you, and share the list with your doctor and pharmacist.

OVERDOSE: If overdose is suspected, contact your local poison control center or emergency room immediately. US residents can call the US national poison hotline at 1-800-222-1222. Canadian residents should call their local poison control center directly. Symptoms of overdose may include: slow breathing, slurred speech, or a deep sleep from which you cannot be awakened.

NOTES: Do not share this medication with others. It is against the law.

This medication has been prescribed for your current condition only. Do not use it later for another condition unless told to do so by your doctor. A different medication may be necessary in those cases.

Laboratory and/or medical tests (e.g., liver and kidney function tests, blood count) may be performed periodically to check for side effects if you use this drug for an extended period of time. Consult your doctor for more details.

If you require treatment for more than 7-10 days, laboratory and/or medical tests should be performed to find the cause of your sleep problem. Consult with your doctor for more details.

As you get older, your sleep pattern may naturally change and your sleep may be interrupted several times during the night. Consult your doctor or pharmacist for ways to improve your sleep without medication, such as avoiding caffeine and alcohol close to bedtime, avoiding daytime naps, and avoiding going to bed too early each night.

MISSED DOSE: If you miss a dose, take it as soon as you remember if it is still near bedtime. If it is already the next day, resume your usual dosing schedule that night at bedtime. Do not double the dose to catch up.

STORAGE: Store at room temperature below 86 degrees F (30 degrees C) away from light and moisture. Do not store in the bathroom. Keep all medicines away from children and pets.

Do not flush medications down the toilet or pour them into a drain unless instructed to do so. Properly discard this product when it is expired or no longer needed. Consult your pharmacist or local waste disposal company for more details about how to safely discard your product.

Information last revised May 2010. Copyright(c) 2010 First Databank, Inc.

Doral Patient Information Including Side Effects

Brand Names: Doral

Generic Name: quazepam (Pronunciation: KWAY ze pam)

What is quazepam (Doral)?

Quazepam is in a group of drugs called benzodiazepines (ben-zoe-dye-AZE-eh-peens). Quazepam affects chemicals in the brain that may become unbalanced and cause sleep problems (insomnia).

Quazepam is used to treat insomnia symptoms, such as trouble falling or staying asleep.

Quazepam may also be used for other purposes not listed in this medication guide.

Doral 7.5 mg

oblong, orange, imprinted with DORAL, 7.5

What are the possible side effects of quazepam (Doral)?

Stop using quazepam and call your doctor at once if you have a serious side effect such as:

  • worsening insomnia;
  • confusion, anxiety, slurred speech, unusual thoughts or behavior;
  • hallucinations, agitation, aggression;
  • weak or shallow breathing;
  • fast or pounding heartbeats;
  • muscle stiffness in your tongue, jaw, or neck;
  • problems with urination; or
  • jaundice (yellowing of the skin or eyes).

Less serious side effects may include:

  • daytime drowsiness (or during hours when you are not normally sleeping);
  • amnesia or forgetfulness;
  • muscle weakness, lack of balance or coordination;
  • dizziness, vision problems;
  • nightmares;
  • headache, blurred vision, depressed mood;
  • feeling nervous, excited, or irritable;
  • impotence, loss of interest in sex;
  • mild itching or skin rash;
  • nausea, diarrhea, stomach pain, loss of appetite; or
  • dry mouth, increased thirst.

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

Read the Doral (quazepam tablets) Side Effects Center for a complete guide to possible side effects »

What is the most important information I should know about quazepam (Doral)?

Some people using this medicine have engaged in activity such as driving, eating, or making phone calls and later having no memory of the activity. If this happens to you, stop taking quazepam and talk with your doctor about another treatment for your sleep disorder.

Do not use this medication if you are allergic to quazepam or to other benzodiazepines, such as alprazolam (Xanax), chlordiazepoxide (Librium), clorazepate (Tranxene), diazepam (Valium), lorazepam (Ativan), midazolam (Versed), temazepam (Restoril), or triazolam (Halcion).

Before taking quazepam, tell your doctor if you have any breathing problems, kidney or liver disease, or a history of depression, mental illness, suicidal thoughts, or addiction to drugs or alcohol.

Quazepam may be habit-forming and should be used only by the person it was prescribed for. Quazepam should never be shared with another person, especially someone who has a history of drug abuse or addiction. Keep the medication in a secure place where others cannot get to it.

Quazepam should be used for only a short time to treat insomnia. After 7 to 10 nights of use, talk with your doctor about whether or not you should keep taking quazepam.

Side Effects Centers

Doral Patient Information including How Should I Take

What should I discuss with my healthcare provider before taking quazepam (Doral)?

Some people using this medicine have engaged in activity such as driving, eating, or making phone calls and later having no memory of the activity. If this happens to you, stop taking quazepam and talk with your doctor about another treatment for your sleep disorder.

Do not use this medication if you are allergic to quazepam or to other benzodiazepines, such as alprazolam (Xanax), chlordiazepoxide (Librium), clorazepate (Tranxene), diazepam (Valium), lorazepam (Ativan), midazolam (Versed), temazepam (Restoril), or triazolam (Halcion).

If you have any of these other conditions, you may need a dose adjustment or special tests to safely take quazepam.

  • asthma, emphysema, bronchitis, chronic obstructive pulmonary disorder (COPD), or other breathing problems;
  • kidney or liver disease;
  • a history of depression, mental illness, suicidal thoughts or behavior; or
  • a history of drug or alcohol addiction.

FDA pregnancy category X. Quazepam can cause birth defects in an unborn baby. It may also cause withdrawal symptoms in a newborn if the mother takes quazepam during pregnancy. Do not use quazepam if you are pregnant. Tell your doctor right away if you become pregnant during treatment. Use an effective form of birth control while you are using this medication.

Quazepam can pass into breast milk and may harm a nursing baby. Do not use this medication without telling your doctor if you are breast-feeding a baby.

The sedative effects of quazepam may last longer in older adults. Accidental falls are common in elderly patients who take benzodiazepines. Use caution to avoid falling or accidental injury while you are taking quazepam.

Do not give this medication to anyone under 18 years old.

How should I take quazepam (Doral)?

Take this medication exactly as it was prescribed for you. Do not take the medication in larger amounts, or take it for longer than recommended by your doctor. Follow the directions on your prescription label.

Do not take quazepam with food or just after a meal.

Contact your doctor if this medicine seems to stop working as well in helping you fall asleep and stay asleep.

Quazepam should be used for only a short time to treat insomnia. After 7 to 10 nights of use, talk with your doctor about whether or not you should keep taking quazepam. Do not take this medication for longer than 12 weeks without your doctor's advice.

Your insomnia symptoms may return when you stop using quazepam, especially during the first day or two. You may also have unpleasant withdrawal symptoms such as vomiting, stomach pain, muscle cramps, sweating, shaky or unpleasant feeling, or seizure (convulsions). Talk to your doctor about how to avoid withdrawal symptoms when you stop using quazepam.

Quazepam may be habit-forming and should be used only by the person it was prescribed for. Quazepam should never be shared with another person, especially someone who has a history of drug abuse or addiction. Keep the medication in a secure place where others cannot get to it.

Store quazepam at room temperature away from moisture, heat, and light.

Keep track of how many tablets have been used from each new bottle of this medicine. Benzodiazepines are drugs of abuse and you should be aware if any person in the household is using this medicine improperly or without a prescription.

Side Effects Centers

Doral Patient Information including If I Miss a Dose

What happens if I miss a dose (Doral)?

Since quazepam is taken as needed, you are not likely to be on a dosing schedule. Take quazepam only when you have time for several hours of sleep.

What happens if I overdose (Doral)?

Seek emergency medical attention if you think you have used too much of this medicine. An overdose of quazepam can be fatal, especially if you take it with alcohol.

Overdose symptoms may include extreme drowsiness, confusion, and fainting or coma.

What should I avoid while taking quazepam (Doral)?

Do not drink alcohol while taking quazepam. Even alcohol consumed during the day can increase the side effects of quazepam taken at bedtime. Avoid alcohol for several days after taking quazepam, as small amounts of the drug may remain in your body during that time.

Quazepam can cause side effects that may impair your thinking or reactions. Be careful if you drive or do anything that requires you to be awake and alert.

What other drugs will affect quazepam (Doral)?

Cold or allergy medicine, sedatives, narcotic pain medicine, muscle relaxers, and medicine for seizures, depression or anxiety can add to sleepiness caused by quazepam. Tell your doctor if you regularly use any of these medicines, or any other sleep medication.

Tell your doctor about all other medications you use, especially:

  • bupropion (Wellbutrin, Zyban);
  • cyclophosphamide (Cytoxan, Neosar);
  • efavirenz (Sustiva);
  • irinotecan (Camptosar);
  • promethazine (Phenergan); or
  • selegiline (Eldepryl, Emsam, Zelapar).

This list is not complete and there may be other drugs that can interact with quazepam. Tell your doctor about all your prescription and over-the-counter medications, vitamins, minerals, herbal products, and drugs prescribed by other doctors. Do not start a new medication without telling your doctor.

Where can I get more information?

Your pharmacist can provide more information about quazepam.


Remember, keep this and all other medicines out of the reach of children, never share your medicines with others, and use this medication only for the indication prescribed.

Every effort has been made to ensure that the information provided by Cerner Multum, Inc. ('Multum') is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Multum information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Multum does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Multum's drug information does not endorse drugs, diagnose patients or recommend therapy. Multum's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners. The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Multum does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Copyright 1996-2012 Cerner Multum, Inc. Version: 7.03. Revision date: 12/15/2010.

Your use of the content provided in this service indicates that you have read,understood and agree to the End-User License Agreement,which can be accessed by clicking on this link.

Healthwise

Side Effects Centers

توزیع کنندگان این دارو
شرکت های تولید کننده یا وارد کننده دارو

دارونـــما
نوآوری برای سلامت

طراحی و اجرا M.Ramezani
ارتباط با ما Info@darunama.com